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The antiangiogenic agent bevacizumab showed synergistic effects when combined with chemotherapy in advanced breast cancer.
We presently investigated the activity of bevacizumab in combination with chemotherapy, including capecitabine and vinorelbine, and
endocrine therapy, including letrozole (þtriptorelin in premenopausal women), as primary therapy for patients with ER and/or PgR
X10% T2–T4a-c, N0–N2, M0 breast cancer. Biological end point included the proliferative activity (Ki67), whereas clinical end
points were clinical response rate, pathological complete response (pCR) and tolerability. Circulating endothelial cells (CECs) and
their progenitors, as surrogate markers of antiangiogenic activity, were measured at baseline and at surgery.Thirty-six women are
evaluable. A clinical response rate of 86% (95% CI, 70–95) and no pCR were observed; Ki67 was significantly decreased by 71%
(interquartile range,  82%,  62%). Toxicity was manageable: two grade 3 hypertension, four grade 3 deep venous thrombosis and
no grade 42 proteinuria were observed. Treatment significantly decreased the percentage of viable CECs and prevented the
chemotherapy-induced mobilisation of circulating progenitors. Basal circulating progenitors were positively associated with clinical
response. In conclusion, bevacizumab is feasible and active in association with primary chemoendocrine therapy for ER-positive
tumours in terms of proliferation inhibition, clinical response and antiangiogenic activity.
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Preoperative treatment of endocrine-responsive breast cancer is a
matter of debate within the scientific community. The striking
improvement in terms of pathological complete response (pCR)
obtained in endocrine-unresponsive tumours with new schedules
of anthracyclines and taxanes has had a lesser impact in ER- and
PgR-positive tumours, which obtained pCR up to 10% (Mazouni
et al, 2007).
On the other hand, endocrine therapy, although associated
with a high clinical response rate, almost rarely yields pCR (up to
3–6%) (Kaufmann et al, 2006). The association of chemo-
endocrine therapy, not systematically investigated in an appro-
priate population, has obtained discouraging results too
(von Minckwitz et al, 2001; Bottini et al, 2005).
We have investigated earlier the activity of the combination
of a non-anthracycline- and taxane-based chemotherapy with
endocrine therapy in a series of patients with ER- and PgR-
positive tumours (Torrisi et al, 2008). Chemotherapy included six
courses of capecitabine and oral vinorelbine administered
in association with letrozole (þ3-monthly triptorelin, if
premenopausal). The results were rather disappointing, with a
response rate of 62% and no patient obtaining a pCR (Torrisi
et al, 2008).
Angiogenesis represents a key process in the development and
growth of cancer cells at any stage (Folkman, 1971). Vascular
endothelial growth factor (VEGF) is the most potent and specific
angiogenic factor and has been identified as a crucial regulator of
both normal and pathological angiogenesis (Banerjee et al, 2007).
Vascular endothelial growth factor acts as a mitogen for vascular
endothelial cells and stimulates the secretion of enzymes involved
in extracellular matrix degradation. Moreover, VEGF stimulates
paracrine and autocrine signalling in endothelial cells (Banerjee
et al, 2007). The recombinant humanised anti-human VEGF
monoclonal antibody (rhuMAb, bevacizumab) inhibits several
activities of VEGF, including endothelial cell growth, vascular
permeability and angiogenesis (Kim et al, 1993; Willett et al, 2004).
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sBevacizumab has shown substantial activity in breast cancer
and synergism with some chemotherapeutic agents (Sweeney et al,
2001; Cobleigh et al, 2003). The combination of bevacizumab and
vinorelbine was investigated in a phase II study in patients with
refractory advanced breast cancer, and a 31% objective response
rate was observed (Burstein et al, 2002). In a phase III randomised
study in breast cancer patients pretreated with anthracyclines and
taxanes, the addition of bevacizumab significantly increased the
response rate as compared with capecitabine alone (Miller et al,
2005). In untreated metastatic patients, the association of
bevacizumab and paclitaxel significantly improved either response
rate or progression-free survival as compared with paclitaxel alone
(Miller et al, 2007). On the other hand, oestrogens are potent
modulators of angiogenesis. It is thus conceivable that the
combination of an antiangiogenic agent and a hormonal manip-
ulation may result in an increased antitumour activity on an
endocrine-sensitive tumour. In preclinical models, oestrogens
increase endothelial cell proliferation and migration, whereas the
effect of aromatase inhibition on angiogenic factors is less clear. In
fact, in preclinical models, aromatase inhibitors downregulate
VEGF expression, whereas no significant change of serum VEGF
has been observed after preoperative anastrozole (Traina et al,
2007; Banerjee et al, 2008). Preclinical data also suggest that VEGF
is involved in precocious stages of angiogenesis (Relf et al, 1997). It
may thus be speculated that the earlier the angiogenic pathway is
blocked, the greater the clinical effect that may be expected. Given
the encouraging results obtained by the combination of capecita-
bine and vinorelbine in advanced breast cancer and the synergism
with bevacizumab shown by both drugs, we thereby decided to
investigate the combination of bevacizumab, capecitabine and
vinorelbine and endocrine therapy in patients with ER- and/or
PgR-positive locally advanced breast cancer. We defined as the
principal measure of activity, the decrease of proliferation by Ki67,
which has been shown to correlate better with prognosis than the
absolute baseline value (Burcombe et al, 2005; Dowsett et al, 2005).
Clinical activity in terms of either objective response rate, pCR or
the tolerability of the combination was also evaluated.
Finally, with the aim of identifying putative predictors and
biomarkers of antiangiogenic activity, we determined baseline and
post-treatment levels of circulating endothelial cells (CECs), either
viable or apoptotic, and their progenitors and investigated their
correlation with clinical outcome variables.
MATERIALS AND METHODS
Patients
Patients with histologically proven T2–T4a-c, N0–N2, M0, ER
and/or PgR X10% and HER2-negative breast cancer were consi-
dered eligible for the study. Eligibility criteria also included no
earlier chemotherapy/hormonotherapy, Eastern Cooperative Oncol-
ogy Group performance status 0–2, measurable lesions, age between
18 and 70 years, white blood cells X3000 per mm
3, platelets
X100000 per mm
3, aspartate aminotransferase, alanine amino-
transferase, p2.5  upper limit of normal and bilirubin p3mg
per 100ml.
Patients with cardiac disease (congestive heart failure, history of
myocardial infarction within the previous 3 months), severe
vascular disease or uncontrolled concomitant infections were
excluded. In addition, patients with a prior history of bleeding
diathesis or coagulopathy, including deep venous thrombosis
(DVT) or pulmonary embolism, recent (within last 6 months) or
current history of gastrointestinal bleeding and current use of full-
dose or parenteral anticoagulants or chronic daily treatment with
aspirin (greater than 325mgday
 1) were excluded as were patients
with 24h urine protein greater than or equal to 500mg or any
active primary renal disease (excluding infection).
Patients had baseline liver and renal function tests, electrolyte
studies and complete blood count and urine analysis performed
within 2 weeks of inclusion in the study. In addition, bilateral
mammography and breast ultrasound, chest X-ray, abdominal
ultrasound, bone scan or FDG-PET, serum CA 15.3 determination
and electrocardiography were performed within 2 weeks from the
start of treatment. Before starting the treatment and providing a
signed informed consent, patients were submitted to a trucut to
obtain a tumour sample to be stored for gene profiling and further
molecular determination and a blood sample for the determination
of circulating biomarkers (VEGF, CEC and their progenitors).
Blood samples were also obtained before (day  1) and immedi-
ately after surgery (week þ1).
Willing patients were submitted to a trucut after 3 weeks
(first cycle) for assessment of early change in Ki67.
Written informed consent from all patients was obtained. The
protocol was approved by the Ethical Committee.
Treatment
Patients received chemotherapy containing capecitabine
2000mgm
 2 orally on days 1–14, vinorelbine 20mgm
 2 i.v. on
days 1 and 3 (Nole ` et al, 2006), and bevacizumab 15mgkg
 1 i.v. on
day 1 every 3 weeks for eight courses. Bevacizumab (Avastin
s;
Roche, Basel, Switzerland) was administered as a 900 i.v. infusion at
the first administration and as 600 and then 300 infusions in the
following courses. Bevacizumab was provided at no cost by Roche.
A central venous catheter (CVC) in the subclavian or in the jugular
vein contralateral to the site of the tumour was implanted in all
patients before starting bevacizumab.
Endocrine therapy consisted of letrozole 2.5mgday
 1. Treat-
ment started on day 1 of the first course of chemotherapy in
postmenopausal patients. In premenopausal patients, GnRH
analogue (triptorelin 11.25mg every 3 months) started on day 1
of chemotherapy and letrozole was added when oestradiol levels
were in the postmenopausal range according to the IEO laboratory
reference values. The median time to start of letrozole in
premenopausal women was 50 days (interquartile (IQ) range,
42–69 days).
Endocrine treatment was continued until the day of surgery.
Surgery was planned 4 weeks after the last dose of bevacizumab.
Toxicity and dose modifications
Toxicity was evaluated according to NCIC-CTG 3.0 criteria by
clinical and laboratory evaluations at day 21 of each cycle.
Chemotherapy was postponed by 1 week if the blood count on
day 21 showed a neutrophil count o1000 per mm
3 and/or a
platelet count o100000 per mm
3. If on day 28 the neutrophil
count was 41000 per mm
3 and platelet count 4100000 per mm
3,
the treatment was re-administered. If after 2 weeks of treatment
delay (on day 35), haematologic recovery (neutrophils 41000 per
mm
3 and platelets 4100000 per mm
3) was not obtained,
chemotherapy was discontinued.
Bevacizumab was held or definitively suspended in case of three
to four haemorrhagic events, venous or arterial thromboembolic
events, uncontrolled hypertension, grade 4 proteinuria, gastro-
intestinal perforations, wound healing complications and infusion-
related allergic reactions.
Response criteria
Tumour was evaluated at baseline by physical measurement, with
callipers, of the two largest diameters and by means of mammo-
graphy and ultrasound. After four and eight cycles, patients also
had mammography and ultrasound breast examination to assess
response. Clinical responses were evaluated according to both
radiological (breast ultrasound or mammography) and clinical
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sevaluation, by measuring the largest diameters of the tumour, and
graded according to standard RECIST criteria (Therasse et al,
2000).
Patients with stable disease, partial remission or complete
remission were candidates for four more courses of therapy.
Pathological complete remissions were evaluated according to
Kuerer et al (1999). A pCR was defined as the total disappearance
of invasive tumour either in the breast or in the axilla. The
presence of intraductal carcinoma qualified for pCR.
Pathology and immunohistochemistry
All included patients had pathological evaluation performed at the
EIO. Surgical specimens were extensively sampled for the
evaluation of residual tumour after primary chemotherapy as
published earlier.
The immunostained slides were evaluated independently by two
of the authors, as reported earlier. Only nuclear reactivity was
taken into account for ER, PgR and Ki67 antigens. The results were
recorded as the percentage of immunoreactive cells over at least
2000 neoplastic cells.
HER2 status was defined at immunohistochemistry (IHC) as
negative (faint and partial staining in 410% of cells¼1þ) and
equivocal (faint and complete staining in 410% of cells¼2þ). In
the latter cases, fluorescence in situ hybridisation (FISH) was
performed to assess the amplification of the HER2 gene.
Biological measurements
Blood samples were collected at baseline, immediately before
surgery, and 1 week after surgery to estimate any change in CECs
and their progenitors (CEPs).
Peripheral blood samples were collected for measurement of
circulating cells by six flow cytometry. Cell suspensions were
evaluated by FACSCanto (Becton Dickinson, San Jose, CA, USA).
The antibodies used were CD31 and CD146 (EC marker), CD45
(pan-haematopoietic marker), CD133 (AC133, progenitor/stem cell
marker), CD34 (progenitor/stem cells, EC), VEGFR-1, VEGFR-2
and VEGFR-3.
Fluorescently labelled isotype-matched IgG1 antibodies were
used as control for analysis.
Appropriate analysis gates were used to enumerate viable and
apoptotic CECs and CEPs.
After acquisition of at least 1 10
6 cells per blood sample,
analyses were considered as informative when adequate numbers
of events (i.e. 4100) were collected in the CEC enumeration gates.
Circulating endothelial cells were defined as negative for the
haematopoietic marker CD45, positive for the endothelial markers
CD31 and CD146, and negative for the progenitor marker CD133.
Circulating endothelial progenitor cells were depicted by the
expression of CD133. 7AAD was used to gain insight into CEC/CEP
viability according to Philpott et al (1996).
Sorted CECs, investigated by electron microscopy, were found to
be bona fide endothelial cells by the presence of Weibel–Palade
bodies. More than 75% of the circulating mRNAs of the
endothelial-specific gene, VE-cadherin, found in the blood, were
present in the sorted population. Coefficients of variation related
to the CEC and CEP enumeration procedure by flow cytometry
were 4±4 (intrareader), 17±4 (inter-reader) and 17±7%
(variability over 0–72h), respectively (P Mancuso et al,
2008, in press).
Statistical methods
The primary objective of the study was to estimate the effect of
bevacizumab on the change in tumour cell proliferation by
assessment of Ki67, a biomarker of cell proliferation, in breast
cancer tissue at baseline (Ki67T0) and after 24–28 weeks (surgical
resection specimen) of treatment (Ki67T1). The decrease was
expressed in terms of relative reduction within each patient and
calculated as ((Ki67T1–Ki67T0)/Ki67T0) 100.
The secondary efficacy objectives of the study were (a) to assess
the effect of 24 weeks of bevacizumab on the change in tumour
size, as assessed by ultrasound and mammography, and on the
percentage of pCR as defined earlier; (b) to estimate any change in
breast cell proliferation as measured by Ki67 in biopsies after 3
weeks; and (c) to estimate any change in CECs, in their sub-
population and in the circulating progenitors, in blood at baseline,
immediately before surgery, and 1 week after surgery.
According to the historical data collected at our institute on
about 400 T2–T4, N0–N2, M0 breast cancer patients receiving
primary chemotherapy, about 25% of patients had a relative
decrease greater than 80% (Colleoni et al, 2004).
At the design phase, a sample size of 30 patients was planned,
yielding an 80% power to detect a 50% proportion of patients with
a relative decrease of Ki67 levels greater than 80%, twice as great as
the proportion observed in historical controls (25%).
The Fisher’s exact test and the Wilcoxon signed-rank test were
used to evaluate differences in the distribution of categorical and
continuous variables, respectively. The Wilcoxon signed-rank test
was used to evaluate differences within the same patients of
continuous variables measured at two different time points.
Subgroup analyses and/or analyses of secondary end points were
exploratory in nature.
All P-values were two sided. The statistical analyses were run
using SAS version 8.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
From May 2006 to January 2007, 37 patients were enrolled in the
study. One patient was diagnosed with suspicious ischaemic
cerebral alterations at the basal MRI and neither received
bevacizumab nor was considered evaluable. Thirty-six patients
were evaluated for clinical and biological end points.
Baseline characteristics of patients and tumours are reported in
Table 1. Median age was 44 years (range, 30–68). Twenty-five
patients (69%) were premenopausal and 11 (31%) were post-
menopausal as assessed by circulating gonadotrophins and
oestradiol. Eighty-six per cent of tumours were T2–T3 and 69%
were clinically nodal positive (at ultrasound and/or FDG-PET).
As for protocol, all patients had ER X10% tumours, whereas
PgR was positive in 30 out of 36 tumours. HER2 was negative at
IHC in all but one tumour, whereas FISH was negative. At baseline,
Ki67 was 420% in 22 tumours (61%). At surgery, all tumours but
one remained ER positive, whereas PgR switched to a negative
phenotype in 25 out of 30 patients. The patient who switched to a
negative ER phenotype also turned out to be HER2 positive at IHC
and at FISH while remaining IHC 2þ and FISH negative at
baseline.
Responses after treatment are summarised in Table 2. A
complete response was observed in one patient (3%) and a partial
response was observed in 30 patients (83%) with a cumulative
objective response rate of 86% (95% CI, 70–95). Fourteen patients
had pathological negative nodes (39%; 95% CI, 23–56). Breast-
conservative surgery was feasible in 64% of patients (95% CI,
46–79) and was raised to 74%, when excluding T4 tumours, who
were candidated to mastectomy irrespective of response.
In premenopausal patients, letrozole was started at a median of
50 days (IQ range, 43–69) after the first cycle of chemotherapy and
bevacizumab at the achievement of oestradiol levels within the
postmenopausal range. The overall median duration of letrozole
was 139 days (IQ range, 119–168). The median duration of
letrozole was 134 days (IQ range, 111–140) in premenopausal
patients and 183 days (IQ range, 168–203) in postmenopausal
patients, respectively (Po0.0001).
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after treatment, the median value was 5 (IQ range, 3–9.5%). The
median percent decrease was 71% (IQ range,  82%,  62%), with
P-value o0.0001 (Wilcoxon signed-rank test) (Figure 1). Thirty-
one percent of patients (95% CI, 16–48) had a decrease X80%.
The only factor significantly associated with Ki67 decrease 480%
was the duration of letrozole treatment, in that 50% of patients
receiving letrozole for more than the median time (139 days)
experienced a decrease of Ki67 480% as compared with 12% of
patients treated for a shorter time (P¼0.03). When the analysis
was performed according to the menopausal status, this associa-
tion was maintained with a borderline significance in premeno-
pausal patients (140 vs 122 days, P¼0.056), whereas it was
completely lost in postmenopausal patients (191 vs 181 days,
P¼0.45).
On the other hand, the duration of letrozole was not associated
with the likelihood of obtaining a clinical response.
Ki67 was determined after 3 weeks (first cycle of bevacizumab
and chemotherapy) in 17 patients. In these patients, an early
significant decrease was observed (median percent decrease 65%
(IQ range, 44–69%) Po0.001).
Toxicities grade 42 are summarised in Table 3. Bevacizumab
was administered for eight courses in 26 patients. Bevacizumab
Table 2 Response after treatment
No. %
Evaluable patients 36
Pathological complete response 0 0
Clinical response
Complete 1 3
Partial 30 83
Stable disease 5 14
Progression 0 0
Pathological tumour size
T1 15 42
T2 16 44
T3 4 11
T4 1 3
Nodal status at surgery
N0 14 39
N1 9 25
N2 8 22
N3 5 14
Type of surgery
Breast-conserving surgery 23 64
Mastectomy 13 37
Table 1 Patient characteristics at baseline
Characteristics No. of patients %
Total enrolled/evaluable 37/36 —
Age (years)
Median 44
Range 30–68
Menopausal status
Premenopausal 25 69
Postmenopausal 11 31
Clinical tumour size
T2 22 61
T3 9 25
T4 5 14
Clinical nodal status
N0 11 31
N1 22 61
N2 1 3
N3 2 5
PgR status
PgR negative/low 6 17
PgR positive
a 30 83
Ki67
o20% 14 39
X20% 22 61
Nuclear grade
11 3
22 7 7 5
36 1 7
Unknown 2 5
PgR¼progesterone receptor.
aPositive: X10%.
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Figure 1 Change between pre- and post-treatment levels of Ki67 in
each patient.
Table 3 Toxicities grade X2
Grade 2 Grade 3 Grade 4
N % N % N %
Leukopaenia 5 14 5 14 0 ( )
Neutropaenia 4 14 12 14 4 11
Nausea 7 19 0 ( )0(  )
Vomiting 3 5 0 ( )0(  )
Diarrhoea 2 ( )0 (  )0(  )
Stipsis 8 22 1 3 2 8
Mucositis 7 19 2 5 0 ( )
Biochemical
a 51 4 3 80 (  )
Neurological 0 ( )1 30 (  )
Myalgia 1 3 0 ( )0(  )
Asthaenia 5 14 1 3 2 8
Epigastralgia 4 11 0 ( )0(  )
HFS 4 11 1 3 1 4
DVT 0 ( )4 1 10 (  )
Hypertension 7 19 2 5 0 ( )
Proteinuria 1 3 0 ( )0(  )
Infection/fever 2/2 5/5 0/2 0/5 0 ( )
DVT¼deep venous thrombosis; HFS¼hand–foot syndrome.
aIncluded alteration of
liver function (AST, ALT and bilirubin).
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swas discontinued before the fourth cycle in two patients for the
occurrence of DVT of subclavian (one case) and internal giugular
vein (one case), in both cases corresponding to the site of insertion
of the catheter of the CVC. In one further patient, bevacizumab
was discontinued after the sixth cycle because of the occurrence of
a seizure associated with MRI alteration referable to a leukoence-
phalopathy. A DVT of the giugular vein also occurred in this
patient. A DVT of the femoral vein occurred in another patient
after completion of the treatment before surgery. In one patient,
bevacizumab was held for three cycles because of grade 3
hypertension, and two patients received six and seven cycles
because of infection of the CVC and a delay in the implant of
CVA, respectively. In the remaining five patients, treatment
was discontinued before the eighth cycle because of grade 42
chemotherapy-related toxicity. Grade 3 hypertension was observed
in two patients and grade 2 in seven patients, probably related to
bevacizumab administration. One case of grade 2 proteinuria was
observed that did not require drug discontinuation. Grade 1
bleeding, mainly epistaxis, was observed in five patients. No major
surgical complication occurred after surgery except for one case of
infection and one case of wound healing delay.
Measurements of CECs and CEPs were feasible in all patients at
baseline and in 29 patients at surgery, whereas only a small
proportion of patients had blood samples drawn at 1 week after
surgery, and statistical analyses were not performed for the latter
group. Treatment did not significantly affect the total number
of CEPs and CECs, although a trend towards reduction of CECs
was observed (P¼0.07). However, when different sub-populations
of CECs were analysed separately, a significant increase in
apoptotic CECs and a significant decrease in viable CECs was
evident (Figure 2). At the same time, a significant increase in
CD31þVEGFR-1þ was observed.
When we analysed the correlation of biological parameters with
clinical response, we observed that higher levels of baseline CEPs
were positively correlated with the likelihood of obtaining a
clinical response (P¼0.026) (Figure 3) and showed a trend
towards the prediction of a Ki67 decrease 480% (P¼0.08). No
other factor significantly correlated with clinical response, the
likelihood of having pathological negative nodes at surgery or of
obtaining a reduction of proliferative activity 480%.
At the same time, the change of molecular parameters induced
by treatment was not predictive of any clinical outcome variable
except for a significant correlation between the CD31þ/VEGFR-
2þ sub-population of CECs and clinical response (P¼0.017).
DISCUSSION
Preoperative treatment of endocrine-responsive tumours repre-
sents a challenge for medical oncologists. Although ER- and/or
PgR-positive tumours respond poorly to primary chemotherapy in
terms of pCR, long-term prognosis of these tumours is consistently
better compared with that of ER-negative tumours (Guarneri et al,
2006; Colleoni et al, 2008). Different treatment approaches and
surrogate biomarkers of activity are required in this subset of
tumours.
Angiogenesis represents a key process at multiple steps in breast
carcinogenesis (Folkman, 1971). Different from other molecular-
targeted drugs recently recognised in the therapeutic armamen-
tarium of the medical oncologists, antiangiogenic drugs do not
work through interaction with a specific target but by interfere
with a pathway that is shared by all neoplastic cells. It is thus
conceivable that endocrine-responsive tumours may benefit from a
disruption of the angiogenic switch. Literature data confirm that
VEGF expression is a significant prognostic factor of clinical
outcome, irrespective of hormone receptor status (Banerjee et al,
2007). In patients receiving endocrine therapy for advanced breast
cancer, tissutal VEGF levels were inversely related to clinical
response (Foekens et al, 2001; Manders et al, 2003).
Bevacizumab was shown to improve clinical activity of
chemotherapy in advanced breast cancer, although no effect on
overall survival has been observed (Miller et al, 2005, 2007), and
the drug is currently investigated as adjuvant treatment of early
breast cancer in association (concurrently or sequentially) with
chemotherapy. Preclinical data suggest that the role of VEGF is
crucial in the early stages of breast carcinogenesis, and the
implication of an anti-VEGF therapy may be greater the earlier the
treatment is introduced (Relf et al, 1997). The clinical and
molecular activities of a single course of bevacizumab before
adding chemotherapy with docetaxel were assessed in inflamma-
tory breast cancer (Wedam et al, 2006). Significant decreases of
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Figure 2 Circulating endothelial cells (CECs) at baseline and after
surgery. The fraction of viable (white box) and apoptotic CECs (grey box)
contributing to the absolute CEC count is shown.
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Figure 3 Circulating endothelial progenitor cells (CEPs) at baseline
according to clinical response. Whiskers (standard span) were extended to
1.5 times the interquartile range outside the first and third quartiles.
Outliers beyond the standard span were indicated with empty dots.
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sVEGFR-2 and of vascular permeability (assessed by MRI
parameters), correlated with clinical response, were observed
(Wedam et al, 2006). Preliminary data on the combination of
bevacizumab and chemotherapy have consistently reported a
high response rate, although differences in pCR rate have been
observed across studies (Lyons et al, 2006; Wedam et al, 2006;
Greil et al, 2007).
Short-term change of proliferative activity better than baseline
levels after primary chemotherapy and endocrine therapy has been
associated with clinical outcome (Chang et al, 1999; Dowsett et al,
2005). In a randomised study of preoperative therapy, the 2-week
decline of Ki67 was greater after anastrozole as compared with
tamoxifen and the combination of both agents, mirroring the
results in terms of DFS obtained in the phase III randomised trial
of adjuvant therapy with the three (Dowsett et al, 2005). The
proliferative activity at surgery was also shown as a significant
independent predictor of long-term outcome after primary
chemotherapy (Jones et al, 2007). In our study, a dramatic
decrease of Ki67 was observed after treatment, with a median post-
treatment value of 5%. In addition, about one-third of patients
achieved a decrease 480%. Interestingly, the likelihood of
achieving a greater decrease was positively correlated with the
duration of endocrine treatment, underscoring the relevance of an
endocrine manipulation in patients with endocrine-responsive
tumours. However, given the multiplicity of treatments and the
limited number of patients considered, it is not possible to assess
how the single treatment contributed to this dramatic decrease of
proliferative activity. Limited data are available with the combina-
tion of bevacizumab and endocrine therapy, although preliminary
data show a promising activity of the combination of bevacizumab
and letrozole as primary therapy in postmenopausal women with
ER-positive breast cancer (Forero-Torres et al, 2007).
Although it has been proposed that assessing an antiangiogenic
treatment by measuring tumour shrinkage may not fully reflect the
antitumour activity of the drug, in this study, we observed that 86%
of imaging confirmed clinical responses, a significant figure in this
population of patients. In addition, the proportion of patients with
pathological negative nodes is comparable with that reported in a
population of ER-positive patients treated with anthracylines and
taxanes containing chemotherapy (Guarneri et al,2 0 0 6 ) .A f t e r
treatment, 74% of T2–T3 tumours were treated with conservative
surgery, which represents an appreciable figure. In an earlier study
with capecitabine and oral vinorelbine in association with endocrine
therapy in a similar population of patients, we observed a clinical
response rate and a breast-conserving surgery rate of 62% (Torrisi
et al, 2008). Although recognising the limitation of an indirect
comparison and that other factors such as the longer duration of
treatment (eight vs six courses) and the different routes of
vinorelbine administration (intravenous vs oral) may have con-
curred with this difference, the addition of bevacizumab appeared to
increase the clinical response and the breast-conserving rate as
compared with chemoendocrine therapy, although not affecting the
likelihood of obtaining pathological complete remission. The value
of pCR as a surrogate end point of clinical outcome in ER-positive
tumours after primary chemotherapy has been questioned, given the
inconsistent results deriving from the analysis of retrospective series
(Ring et al,2 0 0 4 ;G u a r n e r iet al, 2006). The limited number of pCRs
observed in both series among ER-positive tumours may account
for this inconsistency, and the search for other markers to assess
that the value of preoperative therapy in this sub-population is
strongly encouraged.
The identification of surrogate markers of antiangiogenic
activity different from standard tumour measurement appears
crucial for monitoring drug efficacy and for designing an optimal
integration with conventional antitumoral strategies (Bertolini
et al, 2006). An increase of apoptotic CECs was shown to positively
correlate with clinical response and clinical benefit in patients
treated with metronomic chemotherapy (Mancuso et al, 2006). In
patients treated with neoadjuvant chemotherapy, significantly
higher levels of CECs were observed in patients with ER-negative
as compared with ER-positive tumours; in addition, an increase
in CEPs as well as a reduction of CECs was observed after
neoadjuvant chemotherapy (Furstenberger et al, 2006). An
increase in CECs also predicted a worse outcome in patients with
metastatic breast cancer receiving the combination of bevacizumab
and letrozole (Traina et al, 2007). In our study, baseline levels
of CECs in patients with newly diagnosed and localised
breast cancer were lower than those observed in patients with
advanced disease, supporting the hypothesis that the synthesis of
proangiogenic factors increases along with tumour progression
(Relf et al, 1997).
As expected, treatment increased the proportion of apoptotic
CECs while reducing the viable CECs. However, this effect was not
correlated with any of the clinical outcome variables considered.
A body of evidence suggests that CEPs are mobilised by chemo-
therapy (Bertolini et al, 2003; Furstenberger et al, 2006). As we did
not observe any modulation of CEPs, we may speculate that
bevacizumab prevented the chemotherapy-induced mobilisation of
CEPs, as already shown in preclinical models (Shaked et al, 2006).
On the other hand, given the positive correlation between higher
baseline levels of circulating progenitors and the likelihood of
obtaining a clinical response and the involvement of CEPs in
neovascularisation, we may further speculate that these are
patients who may benefit more from an antiangiogenic manipula-
tion. In addition, we observed a significant correlation between the
modulation of CD31þ/VEGFR-2þ and the likelihood of obtain-
ing a clinical response, in that patients who responded to
treatment did not experience an increase of this sub-population
of CEC. CD31þ/VEGFR-2þ cells are crucial in the neovascular-
isation process and have recently been shown to be elevated in
breast cancer patients to significantly correlate with tumour size
and to rapidly decline after removal of the tumour, suggesting
a possible induction by tumour-driven angiogenic stimuli
(Richter-Ehrenstein et al, 2007).
CD31þVEGFR-1þ CECs, a sub-population that still lacks an
in-depth biological characterisation, were found to be significantly
increased by treatment. Further studies have been planned to
better understand this phenomenon.
The manner in which bone marrow-derived progenitor cells
contribute to neovascularisation either after differentiation in
mature endothelial cells or after homing to sites of angiogenesis is
still a matter of debate (Shaked et al, 2005). Our findings are
consistent in showing that antiangiogenic treatment is also able to
induce in vivo a biological response in terms of inhibition of the
CEC and their progenitors involved in the angiogenic process. In
addition, there is a suggestion towards the usefulness of some of
these populations in monitoring biological activity, given the
observed correlation with clinical response. These hypotheses
should further be exploited in larger subsets of patients.
We showed that bevacizumab may also be safely administered in
the neoadjuvant setting with two minor postsurgical complica-
tions, which may be attributed to the antiangiogenic treatment.
The rate of bevacizumab-related adverse events was consistent
with previous data, except for 11% of DVT, which was greater than
that reported in the phase III trials (Miller et al, 2007). However,
the presence of a CVC and the concurrent use of cytotoxic agents,
as vinorelbine, potentially inducing an endothelial damage may
have concurred with this figure. Hypertension was in most cases
grade 2 and was easily managed with therapy. It required drug
discontinuation in only one case, whereas proteinuria was
negligible.
In conclusion, the combination of bevacizumab, endocrine
therapy and tailored chemotherapy induced a high clinical
response rate in ER-positive breast cancer, whereas proliferative
activity of the tumour was dramatically reduced by the treatment.
Moreover, the duration of endocrine treatment with letrozole
Preoperative bevacizumab for ER-positive breast cancer
R Torrisi et al
1569
British Journal of Cancer (2008) 99(10), 1564–1571 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
scorrelated positively with the chance of obtaining a greater Ki67
decrease. Molecular analyses showed that treatment significantly
reduced viable cells. Interestingly, it also appeared to prevent
chemotherapy-induced CEP mobilisation, thus interfering with
neovascularisation. In addition, patients with higher baseline levels
of CEPs were more likely to experience a clinical response.
Further studies investigating optimal timing, duration and
combination of antiangiogenic agents with conventional antineo-
plastic drugs, and particularly the identification of surrogate
markers of antiangiogenic activity, are warranted.
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